Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.60 |
| ▸ | NAAA | Q02083 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544056 | 1.00 | CRBN (0.60) | CRBNDDB1NAAAALDH1A1GAA | |
| SCHEMBL5200673 | 1.00 | CRBN (0.60) | CRBNDDB1NAAAALDH1A1GAA | |
| SCHEMBL1903249 | 0.90 | CRBN (0.53) | CRBNDDB1NAAAALDH1A1GAA | |
| SCHEMBL5180974 | 0.87 | NAAA (0.58) | NAAAALDH1A1GAATSHRASAH1 | |
| SCHEMBL3930648 | 0.87 | NAAA (0.58) | NAAAALDH1A1GAATSHRASAH1 | |
| SCHEMBL765661 | 0.87 | NAAA (0.58) | NAAAALDH1A1GAATSHRASAH1 | |
| SCHEMBL19207870 | 0.85 | RIPK1 (0.57) | NAAAALDH1A1GAATSHR | |
| SCHEMBL1976229 | 0.85 | RIPK1 (0.57) | NAAAALDH1A1GAATSHR | |
| SCHEMBL7426649 | 0.85 | RIPK1 (0.57) | NAAAALDH1A1GAATSHR | |
| SCHEMBL425375 | 0.82 | ALDH1A1 (0.58) | NAAAALDH1A1GAATSHRCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013005229-A1 | PROCESS FOR LENALIDOMIDE | HETERO RESEARCH FOUNDATION (IN) | 2013-01-10 | — | — | WO | claimed |
| CN-105440014-A | Preparation method of lenalidomide | HANGZHOU HEZE PHARMACEUTICAL TECH CO LTD | 2016-03-30 | — | — | CN | disclosed |
| CN-104797256-A | Methods for the treatment of locally advanced breast cancer | CELGENE CORP | 2015-07-22 | — | — | CN | disclosed |
| US-20140309436-A1 | THALIDOMIDE ANALOGS | P2D, INC. | 2014-10-16 | — | — | US | disclosed |
| US-8853253-B2 | Thalidomide analogs | P2D, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| CN-103688176-A | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor | CELGENE CORP | 2014-03-26 | — | — | CN | disclosed |
| US-8546430-B2 | Thalidomide analogs | P2D, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2438053-B1 | METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) | 2013-09-11 | — | — | EP | disclosed |
| US-8524742-B2 | Use of 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-09-03 | — | — | US | disclosed |
| US-8524742-B2 | Use of 5H-thioeno(3,4-c)pyrrole-4,6-dione derivatives as tumor necrosis factor inhibitor | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2013-09-03 | — | — | US | disclosed |
| EP-1957481-A1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | Grünenthal GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| WO-2008007979-A1 | (2,6-DIOXO-3-PIPERINYL)AMIDOBENZOIC IMMUNOMODULATORY AND ANTI-CANCER DERIVATIVES | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007062817-A1 | PYRROLIDIN(THI)ONES HETEROCYCLICALLY SUBSTITUTED IN 3-POSITION | Grünenthal GmbH (DE) | 2007-06-07 | — | — | WO | disclosed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004022536-A1 | NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LIMITED (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211728-A1 | Thalidomide analogs | TNF, TNFRSF1A, PGF | CRBN 321/4885DDB1 953/4885NAAA 2890/4885 |
| US-20140309436-A1 | THALIDOMIDE ANALOGS | TNF, TNFRSF1A, TNFRSF9 | CRBN 241/4885DDB1 919/4885NAAA 3246/4885 |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, CD40 | CRBN 938/4885DDB1 1951/4885NAAA 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.